Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
November 3, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
- Medicare product coverage strategy
- Proper planning for product pricing
- Preparing comparative effectiveness data
- Working with payer expectations
- Data that should be in place for partnering or acquisition deals
Panelists:
- Judith A. Waltz, Partner, Foley & Lardner LLP
- Anita Chawla, Ph.D., Vice President, Analysis Group
- Antoun Nabhan, Director of Corporate Development, Onyx Pharmaceuticals
Related Insights
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…